ArticleDigestive diseases and sciences2007
Fructo-oligosaccharide reduces inflammation in a dextran sodium sulphate mouse model of colitis.
Article in Digestive diseases and sciences, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 53 citations in OpenAlex.
- Broussoflavonol F Alleviates Obesity-Associated Metabolic Syndrome in Obese Mice by Modulating Gut Microbiota.Molecular nutrition & food research · 2026Article
- The oligosaccharides of Xiasangju alleviates dextran sulfate sodium-induced colitis in mice by inhibiting inflammation.PloS one · 2023Article
- Physiological Characteristics ofJournal of microbiology and biotechnology · 2021Article
- Article
- Inhibitory Effect of Steamed Soybean Wastewater Against DSS-Induced Intestinal Inflammation in Mice.Foods (Basel, Switzerland) · 2020Article
- Inflammatory bowel disease and immunonutrition: novel therapeutic approaches through modulation of diet and the gut microbiome.Immunology · 2018Review
- Anti-inflammatory effects of newly synthesized α-galacto-oligosaccharides on dextran sulfate sodium-induced colitis in C57BL/6J mice.Food research international (Ottawa, Ont.) · 2018Article
- Prebiotic Supplementation Following Ileocecal Resection in a Murine Model is Associated With a Loss of Microbial Diversity and Increased Inflammation.Inflammatory bowel diseases · 2017Article
- Oligomannan Prebiotic Attenuates Immunological, Clinical and Behavioral Symptoms in Mouse Model of Inflammatory Bowel Disease.Scientific reports · 2016Article
- Fructooligosaccharides exert intestinal anti-inflammatory activity in the CD4+ CD62L+ T cell transfer model of colitis in C57BL/6J mice.European journal of nutrition · 2016Article
- Nutritional Keys for Intestinal Barrier Modulation.Frontiers in immunology · 2015Review
- Pathobiology and potential therapeutic value of intestinal short-chain fatty acids in gut inflammation and obesity.Digestive diseases and sciences · 2013Review
- The interplay between fiber and the intestinal microbiome in the inflammatory response.Advances in nutrition (Bethesda, Md.) · 2013Review
- Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility.BioMed research international · 2013Review
- Modulation of PPAR-γ by Nutraceutics as Complementary Treatment for Obesity-Related Disorders and Inflammatory Diseases.PPAR research · 2012Article
- Role of the gut microbiota in defining human health.Expert review of anti-infective therapy · 2010Review
- Prebiotics in chronic intestinal inflammation.Inflammatory bowel diseases · 2009Review
- Nitric oxide as a target of complementary and alternative medicines to prevent and treat inflammation and cancer.Cancer letters · 2008Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fructo-oligosaccharide (FOS) is a prebiotic that stimulates the colonic growth of bifidobacteria to promote intestinal health. This study assessed whether FOS can reduce intestinal damage associated with ulcerative colitis and accelerate recovery in a mouse model. C57BL/6 mice received 2% dextran sulphate sodium for 7 days (days 8-14). FOS (1.5 g/mL) treatment was administered twice daily (n=10/group): before and during colitis (days 1-14); during colitis (days 10-14); and during colitis and the recovery period (days 10-19). Disease activity was scored daily and colonic damage was assessed by histological analysis. FOS treatment significantly reduced disease activity and damage in the distal colon (P < .05). Treatment with FOS (days 10-14) had increased crypt depth (116+/-6 microm) compared to water treatment (90+/-4 microm, P < .05). FOS treatment (days 10-19) produced a faster recovery from damage with increased crypt depth and crypt area. These results demonstrate the protective effect of FOS treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.